SG10201709955PA - Methods of treatment and compositions with xanthine oxidase inhibitors - Google Patents

Methods of treatment and compositions with xanthine oxidase inhibitors

Info

Publication number
SG10201709955PA
SG10201709955PA SG10201709955PA SG10201709955PA SG10201709955PA SG 10201709955P A SG10201709955P A SG 10201709955PA SG 10201709955P A SG10201709955P A SG 10201709955PA SG 10201709955P A SG10201709955P A SG 10201709955PA SG 10201709955P A SG10201709955P A SG 10201709955PA
Authority
SG
Singapore
Prior art keywords
compositions
treatment
methods
xanthine oxidase
oxidase inhibitors
Prior art date
Application number
SG10201709955PA
Inventor
Lhanoo Gunawardhana
Vijay Gupte
Himanshu Naik
Michael Mayer
Kanji Komatsu
Original Assignee
Takeda Pharmaceuticals Usa Inc
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Usa Inc, Teijin Pharma Ltd filed Critical Takeda Pharmaceuticals Usa Inc
Publication of SG10201709955PA publication Critical patent/SG10201709955PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201709955PA 2013-05-31 2014-05-30 Methods of treatment and compositions with xanthine oxidase inhibitors SG10201709955PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361829759P 2013-05-31 2013-05-31
US201361839609P 2013-06-26 2013-06-26

Publications (1)

Publication Number Publication Date
SG10201709955PA true SG10201709955PA (en) 2018-01-30

Family

ID=50983231

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201509738RA SG11201509738RA (en) 2013-05-31 2014-05-30 Methods of treatment and compositions with xanthine oxidase inhibitors
SG10201709955PA SG10201709955PA (en) 2013-05-31 2014-05-30 Methods of treatment and compositions with xanthine oxidase inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201509738RA SG11201509738RA (en) 2013-05-31 2014-05-30 Methods of treatment and compositions with xanthine oxidase inhibitors

Country Status (9)

Country Link
US (2) US20140357683A1 (en)
JP (2) JP2016520133A (en)
CN (1) CN105579037A (en)
CA (1) CA2913755A1 (en)
MX (1) MX2015016494A (en)
PH (1) PH12015502679A1 (en)
SG (2) SG11201509738RA (en)
TW (1) TW201536284A (en)
WO (1) WO2014194226A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3368030A4 (en) * 2015-10-28 2019-05-01 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of dimethyl fumarate
CN105769766B (en) * 2016-03-24 2018-07-06 长沙佰顺生物科技有限公司 A kind of Topiroxostat nano-emulsion and preparation method thereof
JP7108384B2 (en) * 2016-07-13 2022-07-28 日本ケミファ株式会社 Orally disintegrating tablet of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid
EA201990333A1 (en) * 2016-07-18 2019-10-31 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH Gout or Hyperuricemia
WO2020246528A1 (en) 2019-06-04 2020-12-10 日本ケミファ株式会社 Therapeutic for gout or hyperuricemia
KR20220168173A (en) * 2021-06-15 2022-12-22 주식회사 엘지화학 A pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazol-4-carboxyl acid
CN115252567A (en) * 2022-07-08 2022-11-01 广西纯正堂制药有限公司 Febuxostat osmotic pump sustained-release tablet and preparation method thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5573776A (en) 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5544163A (en) 1994-03-08 1996-08-06 Excel, Inc. Expandable telecommunications system
KR100981905B1 (en) 2002-03-28 2010-09-13 데이진 화-마 가부시키가이샤 Solid preparation containing single crystal form
JP4914210B2 (en) 2004-06-14 2012-04-11 日本ケミファ株式会社 Condensed pyrimidine derivatives and xanthine oxidase inhibitors
US7816558B2 (en) 2005-10-07 2010-10-19 Astellas Pharma Inc. Triarylcarboxylic acid derivative
MX2009007680A (en) * 2007-01-19 2011-08-03 Takeda Pharmaceuticals North America Inc Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents.
ES2429148T3 (en) 2009-03-31 2013-11-13 Kissei Pharmaceutical Co., Ltd. Indolizine derivative and its use for medical purposes
CN101773498B (en) * 2009-12-30 2012-06-20 青岛黄海制药有限责任公司 Preparation method of oral slow/controlled-release preparation containing febuxostat
EP2582812B1 (en) 2010-06-16 2018-01-24 Takeda Pharmaceuticals U.S.A., Inc. Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
AR081935A1 (en) 2010-06-16 2012-10-31 Teijin Pharma Ltd TABLET WITH CONTROLLED RELEASE COVERED NUCLEUS
CN102641255A (en) * 2012-05-08 2012-08-22 南方医科大学 Febuxostat osmotic pump controlled release tablet for treating gout and preparation method

Also Published As

Publication number Publication date
CN105579037A (en) 2016-05-11
WO2014194226A3 (en) 2015-05-14
MX2015016494A (en) 2016-11-18
JP2016520133A (en) 2016-07-11
JP2019108356A (en) 2019-07-04
US20180311217A1 (en) 2018-11-01
US20140357683A1 (en) 2014-12-04
WO2014194226A2 (en) 2014-12-04
PH12015502679A1 (en) 2016-03-07
CA2913755A1 (en) 2014-12-04
SG11201509738RA (en) 2015-12-30
TW201536284A (en) 2015-10-01

Similar Documents

Publication Publication Date Title
HK1225654A1 (en) Compositions and methods for the treatment of presbyopia
HK1210957A1 (en) Effluz inhibitor compositions and methods of treatment using the same
GB201320723D0 (en) Composition and methods of treatment
EP2964651A4 (en) Bmp inhibitors and methods of use thereof
HUE055662T2 (en) Small molecule inhibitors of lactate dehydrogenase and methods of use thereof
HK1255851A1 (en) Heterocyclic inhibitors of erk and methods of use
EP2970311A4 (en) Bmp inhibitors and methods of use thereof
EP2964235A4 (en) Antimicrobial-antibiofilm compositions and methods of use thereof
IL259801A (en) Inhibitors of ezh2 and methods of use thereof
HRP20181291T1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
HK1224210A1 (en) Methods and compositions for treatment of fibrosis
SG11201509738RA (en) Methods of treatment and compositions with xanthine oxidase inhibitors
EP2991627A4 (en) Blood substitute composition and method of use
IL240695A0 (en) Nme inhibitors and methods of using nme inhibitors
IL245123A0 (en) Sirna and their use in methods and compositions for inhibiting the expression of the orai1 gene
SG11201603506PA (en) Treatment of damaged nerve with pten inhibitor
HK1220374A1 (en) Compositions and methods for the treatment of carboxyhemoglobinemia
PL3082845T3 (en) Methods and compositions for treatment of peripheral neuropathies
PT3083848T (en) Composition and method for wood or derivatives of wood
GB201310349D0 (en) Composition and method of use thereof
GB201301928D0 (en) Composition and method of use thereof